The biotechnology sector is currently defined by a high-stakes race toward more human-relevant drug discovery models. The Global Organoids Services Industry is a critical beneficiary of this shift, with recent news highlighting a wave of strategic acquisitions, facility expansions, and AI-driven technological breakthroughs. According to The Insight Partners, this market is on track to reach US$ 15.01 billion by 2031, expanding at a formidable CAGR of 22.3% from its 2023 valuation of US$ 3.03 billion.

As of 2026, the industry has transitioned from "proof-of-concept" research to industrialized, service-oriented production. High-profile developments are increasingly focused on scalability and the integration of automation to solve the reproducibility challenges that historically hindered 3D cell culture.

Recent Strategic Developments and Market News

The last 24 months have seen several milestone events that are reshaping the competitive landscape of organoid services.

1. Landmark Mergers & Acquisitions (2024–2025)

• Merck KGaA Acquires HUB Organoids (January 2025): In one of the most significant moves in the sector, Merck KGaA finalized its acquisition of HUB Organoids Holding B.V. (Utrecht). This deal unites HUB’s foundational patent portfolio on patient-derived organoid (PDO) technology with Merck’s global life science infrastructure, accelerating the commercial availability of standardized 3D models.

Figure out what’s there in this deal| Get a glimpse through a sample at - https://www.theinsightpartners.com/sample/TIPRE00039302

• BioIVT Acquires ZenBio (August 2024): This acquisition strengthened BioIVT's position in advanced cell products and services, expanding its expertise in skin-based models and primary cell isolation for the pharmaceutical and cosmetics industries.

2. Facility Expansions and Industrialization

• Molecular Devices Cardiff Facility (June 2024): Molecular Devices officially opened a multimillion-pound, purpose-built facility in Cardiff, UK. This site is dedicated to the large-scale, quality-controlled production of PDOs using innovative bioreactor technology. The facility is a cornerstone of their 3D Ready™ Organoid Expansion Service, allowing researchers to access "ready-to-plate" cryopreserved organoids at an industrial scale.

3. AI and Automation Breakthroughs (2025–2026)

• Automated Brain Organoid Cultivation (August 2025): Molecular Devices unveiled a major upgrade to its CellXpress.ai® system, integrating "rocking incubation." This breakthrough reduced the weekly manual labor for maintaining complex brain organoids by nearly 90%, accelerating research into neurodegenerative diseases like Alzheimer’s and Parkinson’s.
• AI-Enhanced High-Content Screening (HCS): 2025 trends saw the widespread adoption of AI-powered decision-making in organoid screening, helping service providers minimize variability and track the entire "cell journey" over extended timescales.

4. New Service & Platform Launches

• InSphero’s Cardiac Platform (May 2024): InSphero entered a strategic partnership with Genome Biologics to commercialize a 3D Cardiac Organoid Platform, providing precise, disease-specific models for heart disease research.
• IntegriGut Screen (January 2024): HUB Organoids launched the IntegriGut Screen, a specialized service offering designed specifically for Inflammatory Bowel Disease (IBD) drug discovery.

Top Industry Players Shaping the Market

The current market hierarchy is dominated by firms that have successfully bridged the gap between biological complexity and commercial scalability:

• Merck KGaA (including HUB Organoids)
• Molecular Devices, LLC (A Danaher Company)
• STEMCELL Technologies Inc.
• Crown Bioscience (JSR Life Sciences)
• InSphero
• Thermo Fisher Scientific Inc.
• Corning Incorporated
• DefiniGEN Ltd.
• Synthego
• Organoid Therapeutics

2031 Outlook: The Regulatory Tailwinds

A recurring theme in recent market news is the impact of the FDA Modernization Act 2.0. By removing the statutory mandate for animal testing in drug applications, the law has triggered a "gold rush" for organoid service providers. By 2031, it is expected that the majority of pre-clinical IND (Investigational New Drug) submissions will include data derived from human organoid services, further solidifying the sector's 22.3% CAGR.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: [email protected]
Phone: +1-646-491-9876

Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish